NTRK1 · Variant type: fusion · Fusion partner: TPM3
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Alpelisib | 100.0% | 0.0% | 97.22 |
| 2 | Entrectinib | 100.0% | 0.0% | 93.69 |
| 3 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 4 | Repotrectinib | 99.3% | 0.7% | 84.21 |
| 5 | Pacritinib | 99.2% | 0.8% | 88.64 |
| 6 | Gilteritinib | 99.1% | 0.9% | 88.97 |
| 7 | Crizotinib | 99.0% | 1.0% | 91.39 |
| 8 | Ponatinib | 98.7% | 1.3% | 78.23 |
| 9 | Tenalisib | 98.6% | 1.4% | 97.98 |
| 10 | Nintedanib | 98.6% | 1.4% | 90.23 |
| 11 | Bosutinib | 98.0% | 2.0% | 87.22 |
| 12 | Sunitinib | 98.0% | 2.0% | 91.73 |
| 13 | Defactinib | 97.9% | 2.1% | 92.68 |
| 14 | Fedratinib | 95.6% | 4.4% | 96.21 |
| 15 | Lorlatinib | 95.1% | 4.9% | 97.24 |
| 16 | Darovasertib | 93.9% | 6.1% | 96.99 |
| 17 | Cabozantinib | 93.8% | 6.2% | 92.73 |
| 18 | Alectinib | 88.6% | 11.4% | 95.49 |
| 19 | Tivozanib | 88.3% | 11.7% | 92.42 |
| 20 | Brigatinib | 85.7% | 14.3% | 82.96 |
| 21 | Axitinib | 85.4% | 14.6% | 93.23 |
| 22 | Ripretinib | 79.2% | 20.8% | 92.95 |
| 23 | Ruxolitinib | 73.2% | 26.8% | 98.25 |
| 24 | Futibatinib | 70.0% | 30.0% | 98.48 |
| 25 | Tepotinib | 69.0% | 31.0% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Alpelisib | 100.0% | 97.5% | +2.5% |
| Entrectinib | 100.0% | 99.0% | +1.0% |
| Pralsetinib | 100.0% | 98.7% | +1.3% |
| Repotrectinib | 99.3% | 98.9% | +0.4% |
| Pacritinib | 99.2% | 89.4% | +9.8% |
| Gilteritinib | 99.1% | 92.6% | +6.5% |
| Crizotinib | 99.0% | 95.8% | +3.1% |
| Ponatinib | 98.7% | 98.4% | +0.3% |
| Tenalisib | 98.6% | 59.0% | +39.6% |
| Nintedanib | 98.6% | 93.8% | +4.8% |
| Bosutinib | 98.0% | 67.0% | +31.0% |
| Sunitinib | 98.0% | 82.8% | +15.2% |
| Defactinib | 97.9% | 80.3% | +17.6% |
| Fedratinib | 95.6% | 56.2% | +39.4% |
| Lorlatinib | 95.1% | 63.2% | +31.9% |
| Darovasertib | 93.9% | — | — |
| Cabozantinib | 93.8% | 93.6% | +0.2% |
| Alectinib | 88.6% | — | — |
| Tivozanib | 88.3% | 85.7% | +2.7% |
| Brigatinib | 85.7% | — | — |
| Axitinib | 85.4% | — | — |
| Ripretinib | 79.2% | 93.6% | -14.4% |
| Ruxolitinib | 73.2% | — | — |
| Futibatinib | 70.0% | — | — |
| Tepotinib | 69.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.1ms